HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Deerfield Management Company, L.P.
Frazier Healthcare Partners
Qiming Venture Partners
RA Capital Management